Clay T. Cramer - Concepedia

Author

Clay T. Cramer

Esperion Therapeutics (United States)

Also Known As

C T Cramer, C.T. Cramer, Clay Cramer, Clay T Cramer, Clay T. Cramer

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Esperion Therapeutics (United States)W.E. Upjohn Institute for Employment Research State Street (United States)Alchem Laboratories (United States)Pfizer (United States)

About

Clay T. Cramer is an author at Esperion Therapeutics (United States) specializing in medicine, pharmacology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	318
2	Health Sciences	7	7	95
3	Biochemistry	7	7	118
4	Cell Biology	3	3	137
5	Natural Sciences	2	2	52

Clay T. Cramer

Publications

887

Citations

H-Index

Page 1

	Year	Citations
AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism Stephen L. Pinkosky, Jeffrey C. Hanselman, Cheryl D. Bradshaw, Journal of Lipid Research	2012	225
The Madin Darby Canine Kidney (MDCK) Epithelial Cell Monolayer as a Model Cellular Transport Barrier Moo J. Cho, David P. Thompson, Clay T. Cramer, Pharmaceutical Research	1989	193
ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK Stephen L. Pinkosky, Richard J. Lister, Catherine Pawloski, Journal of Lipid Research Lipid PeroxidationImmunologyImmune RegulationOxidative StressMacrophage Ampk	2013	84
Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial Narendra D. Lalwani, Jeffrey C. Hanselman, Diane MacDougall, Journal of clinical lipidology Hypercholesterolemic PatientsCardiovascular DiseaseMedicineRandomized Placebo-controlled TrialHyperlipidemia	2019	75
Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome Clay T. Cramer, Brian D. Goetz, Krista L. Hopson, Journal of Lipid Research	2004	70
Upregulation of glucose‐6‐phosphate dehydrogenase in response to hepatocellular oxidative stress: Studies with diquat Clay T. Cramer, Susan E. Cooke, Leonard C. Ginsberg, Journal of Biochemical Toxicology	1995	37
An in Vitro Fluorescence Assay for the Detection of Drug-Induced Cytoplasmic Lamellar Bodies Roger G. Ulrich, Kenneth S. Kilgore, E Sun, Toxicology Methods Lipid AnalysisImmunocytochemical TechniqueDermatologyLipid MovementCellular Physiology	1991	35
Disruption of mitochondrial activities in rabbit and human hepatocytes by a quinoxalinone anxiolytic and its carboxylic acid metabolite Roger G. Ulrich, James A. Bacon, Clay T. Cramer, Toxicology Carboxylic Acid MetaboliteMitochondrial FunctionBiochemistryMedicineLiver Physiology	1998	20
Acute Hepatocellular Effects of Erythromycin, Gentamicin, and Trospectomycin in the Perfused Rat Liver: Lack of Correlation between Lamellar Body Induction Potency and Cytotoxicity Jeffrey W. Cox, Roger G. Ulrich, Philip G. Larson, Pharmacology & Toxicology	1988	19
Isolation and culture of hepatocytes from the cynomolgus monkey (Macaca fascicularis) Roger G. Ulrich, Danielle G. Aspar, Clay T. Cramer, In Vitro Cellular & Developmental Biology - Plant HepatologyLiver PhysiologyPhysiologyHistopathologyCell Culture	1990	18

Page 1